Bryleos
Bryleos is a woman-owned and women-led company dedicated to advancing the treatment of multifactorial neurological diseases of aging. They leverage cutting-edge technology such as artificial intelligence and machine learning to develop innovative therapeutics, including NAD+ therapeutics, targeting cellular health to address neurodegenerative diseases like Alzheimer’s, Parkinson’s, ALS, Multiple Sclerosis, and FSHD. Their mission is to transform neurological aging through sustainable, scalable innovations and a systems approach to modulate interconnected pathways involved in neurodegeneration.
Industries
Nr. of Employees
small (1-50)
Products
Oral multifactorial NAD-boosting therapeutic (lead candidate)
Lead oral investigational therapeutic designed to increase intracellular NAD and modulate mitochondrial dysfunction, neuroinflammation, and oxidative stress as a multifactorial metabolic modulator for age-related neurological conditions.
Green solvent-free oral delivery platform
A formulation platform for small molecules intended to improve oral bioavailability and stability while using waterless, low-energy, and solvent-free processes to reduce toxic reagents and trace contamination risk.
IRB-approved randomized double-blind placebo-controlled feasibility study (oral intracellular NAD formulation)
A human feasibility study conducted to evaluate intracellular NAD increases, safety, and exploratory proteomic/metabolomic changes following short-term oral administration of a formulated NAD intervention.
Oral multifactorial NAD-boosting therapeutic (lead candidate)
Lead oral investigational therapeutic designed to increase intracellular NAD and modulate mitochondrial dysfunction, neuroinflammation, and oxidative stress as a multifactorial metabolic modulator for age-related neurological conditions.
Green solvent-free oral delivery platform
A formulation platform for small molecules intended to improve oral bioavailability and stability while using waterless, low-energy, and solvent-free processes to reduce toxic reagents and trace contamination risk.
IRB-approved randomized double-blind placebo-controlled feasibility study (oral intracellular NAD formulation)
A human feasibility study conducted to evaluate intracellular NAD increases, safety, and exploratory proteomic/metabolomic changes following short-term oral administration of a formulated NAD intervention.
Expertise Areas
- Neurodegenerative disease therapeutics
- NAD metabolism and intracellular NAD delivery
- Oral drug formulation and delivery
- Clinical trial design and execution (feasibility studies)
Key Technologies
- Oral formulation technologies
- Solvent-free (waterless) formulation processes
- Intracellular NAD quantification
- Proteomics